DE69624937T2 - Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen - Google Patents

Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen

Info

Publication number
DE69624937T2
DE69624937T2 DE69624937T DE69624937T DE69624937T2 DE 69624937 T2 DE69624937 T2 DE 69624937T2 DE 69624937 T DE69624937 T DE 69624937T DE 69624937 T DE69624937 T DE 69624937T DE 69624937 T2 DE69624937 T2 DE 69624937T2
Authority
DE
Germany
Prior art keywords
recipient
pluripotent cells
mammalian
hematopoietic
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69624937T
Other languages
English (en)
Other versions
DE69624937D1 (de
Inventor
Michael Mardiney
L Malech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH filed Critical National Institutes of Health NIH
Application granted granted Critical
Publication of DE69624937D1 publication Critical patent/DE69624937D1/de
Publication of DE69624937T2 publication Critical patent/DE69624937T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69624937T 1995-07-21 1996-07-22 Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen Expired - Fee Related DE69624937T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US138695P 1995-07-21 1995-07-21
PCT/US1996/012368 WO1997003684A1 (en) 1995-07-21 1996-07-22 Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment

Publications (2)

Publication Number Publication Date
DE69624937D1 DE69624937D1 (de) 2003-01-02
DE69624937T2 true DE69624937T2 (de) 2003-09-04

Family

ID=21695784

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69624937T Expired - Fee Related DE69624937T2 (de) 1995-07-21 1996-07-22 Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen

Country Status (8)

Country Link
US (3) US6103694A (de)
EP (1) EP0871458B1 (de)
JP (1) JPH11509845A (de)
AT (1) ATE228000T1 (de)
AU (1) AU715329B2 (de)
CA (1) CA2227241C (de)
DE (1) DE69624937T2 (de)
WO (1) WO1997003684A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227241C (en) * 1995-07-21 2004-12-21 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
US6051218A (en) * 1996-02-02 2000-04-18 The Regents Of The University Of California Tumor radiosensitization using gene therapy
EP1016413A1 (de) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Menschliches Wachstumshormon (HGH) zur Stimulierung der Mobilisierung pluripotenter Hämatopoietischer Stammzellen
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
US7544355B2 (en) * 2002-03-13 2009-06-09 Universita Degli Studi Di Perugia Methods and compositions for allogeneic transplantation
US20040009158A1 (en) * 2002-07-11 2004-01-15 Washington University Promotion of neovascularization using bone marrow-derived endothelial-progenitor cells
US20050058622A1 (en) * 2002-12-06 2005-03-17 Lyman Stewart D. Methods of using Flt3-Ligand in hematopoietic cell transplantation procedures incorporating nonmyeloablative conditioning regimens
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5106733A (en) * 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
CZ307995A3 (en) * 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
JPH0765602A (ja) * 1993-08-27 1995-03-10 Nippon G Ii Plast Kk 熱可塑性樹脂製リフレクタ
JPH07165602A (ja) * 1993-12-16 1995-06-27 Kirin Brewery Co Ltd 放射線障害防護剤
CA2227241C (en) * 1995-07-21 2004-12-21 THE GOVERNMENT OF THE UNITED STATES, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment

Also Published As

Publication number Publication date
JPH11509845A (ja) 1999-08-31
CA2227241A1 (en) 1997-02-06
AU6639696A (en) 1997-02-18
EP0871458B1 (de) 2002-11-20
WO1997003684A1 (en) 1997-02-06
EP0871458A1 (de) 1998-10-21
CA2227241C (en) 2004-12-21
US6103694A (en) 2000-08-15
US20020182187A1 (en) 2002-12-05
US6863885B2 (en) 2005-03-08
ATE228000T1 (de) 2002-12-15
DE69624937D1 (de) 2003-01-02
AU715329B2 (en) 2000-01-20
US6423311B1 (en) 2002-07-23

Similar Documents

Publication Publication Date Title
DE69624937D1 (de) Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen
ATE71298T1 (de) Immunoregulation.
ATE253631T1 (de) Eine thrombin-blutfraktion zur verwendung in einem medizinischen verfahren
AU9058091A (en) Preparation of nucleic acid samples
ATE250664T1 (de) In vitro reifen von oozyten mit inhibitin/activin kombinationen
GB9308271D0 (en) Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
DE69329779T2 (de) Verfahren zur behandlung geschädigter oder verminderter zellen
ATE79720T1 (de) Verfahren zur konservierung von transplantierbaren, in vitro kultivierten epithelgeweben.
ATE300310T1 (de) Verfahren zur steigerung von hematopoietischen zellen
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
ATE361975T1 (de) Tiermodell für hepatitis-virus infektion
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
FI961440A (fi) Insuliinia erittäviä solulinjoja, valmistusmenetelmiä ja käyttö
DE3879575T2 (de) Alpha-Carotin zur Wachstumshemmung von Krebszellen.
ATE242335T1 (de) Population von mit myeloid-und/oder lymphoid- vorläufern angereicherten zellen und verfahren zur ihrer gewinnung und verwendung
DE69933581D1 (de) Verwendung von humanem wachstumshormon zur vermehrung der anzahl zirkulierender cd34+ zellen, zur wiederherstellung des hämapoietischen- und des immunsystems nach myeloablativer oder antiblastischer therapie, bei transplantation oder re-infusion
ATE322540T1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
DE60308917D1 (de) Verwendung einer Zusammensetzung enthaltend 5-Androsten-3beta,17alpha-diol
ES8800139A2 (es) Mejoras introducidas en el objeto de la patente principal por un procedimiento para la preparacion de derivados de urea.
ATE269090T1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv
FI951325A (fi) Proteiinien kuljetus membraanien välisellä siirrolla ksenogeenisten elinsiirrännäisten esisovittamista varten ja muihin tarkoituksiin
ATE73659T1 (de) Verwendung von cobalt proto-und mesoporphyrin zur herstellungeines arzneimittels zur hemmung des endocrinen systems.
EP0328420A3 (de) De-N-acetylsialsäure enthaltende Ganglioside und ihre Verwendung als Modifikatoren der Zellphysiologie
ATE263833T1 (de) Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen
UA36324A (uk) Спосіб стимуляції гемопоетичної активності кріоконсервованого аломієлотрансплантата

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee